GLP-1 drugs such as Ozempic, Wegovy and Zepbound are increasingly common treatments for diabetes and obesity. They are prescribed as long-term therapies, yet many people stop taking them. An analysis of insurance claims by Dr. Jaime Almandoz, an obesity medicine specialist at UT Southwestern, found fewer than one in four patients remained on a GLP-1 medication after a year.
Patients discontinue for several reasons: some view obesity treatment as temporary and stop after reaching a goal; others face cost or loss of insurance coverage; and side effects also prompt discontinuation. Still, consumer surveys show most people who stop plan to restart. Market-research firm Kantar reports about 74% of lapsers say they are likely or very likely to come back to a GLP-1. That intention is being reinforced as more GLP-1 options appear in pill form, at lower prices, and through online sellers that may bypass traditional doctor and insurer approvals.
Research on intermittent or on-again-off-again GLP-1 use is limited. Existing studies indicate weight tends to return relatively quickly after stopping GLP-1s, faster than with some behavior-focused diet programs. Cultural forces — celebrity examples and social media marketing — have normalized cycling on and off the drugs. Some online ads explicitly imply brief or cosmetic use is acceptable; one compounding pharmacy’s ads showed slim young women and portrayed temporary use as fine, a message regulators have scrutinized.
Pharmaceutical industry groups are pushing for broader access through policy changes and greater oversight of compounding pharmacies that sell GLP-1s directly to consumers.
Clinicians warn about potential harms of repeated short-term use. A significant portion of weight lost on GLP-1s — reported in some studies as around 40% — can be lean muscle. Muscle loss happens with many weight-loss approaches, but GLP-1–associated loss can be pronounced and visible, sometimes described as a bonier, looser-skinned appearance. When people stop the drugs, fat often returns quickly, and it’s unclear how fully or how fast the lost muscle is regained. If lean mass isn’t rebuilt, especially in older adults, repeated cycles could contribute to sarcopenia, impairing balance, mobility, metabolism and bone strength.
Not all experts agree the muscle effects are wholly negative. Some research suggests GLP-1s may improve muscle quality — reducing fat infiltration and producing healthier, stronger muscle fibers — so function might improve even if total muscle mass declines. Clinicians emphasize the importance of assessing not just muscle quantity but its health and function.
Overall, the rise in short-term and intermittent GLP-1 use outpaces evidence about long-term consequences. More research is needed to understand the health effects of stopping and restarting these medications, how to preserve or restore lean mass, and how best to counsel patients weighing the benefits and risks of temporary versus continuous treatment.